BridgeBio Pharma revenue and financials
$66.14Change from previous close: −1.65%Absolute change: −$1.11
In the fiscal year ended December 2025, BridgeBio Pharma reported revenue of $502.08M (+126.26% year over year). The net loss was $732.94M.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +126.26%
- 2025 vs 2024
- Net margin
- -146.0%
- 2024: -244.9%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Total assets | 936 | 919 | 546 | 623 | 1,013 | 704 | 632 |
| Current assets | 798 | 721 | 478 | 549 | 889 | 643 | 569 |
| Cash and equivalents | 570 | 681 | 376 | 377 | 394 | 356 | 364 |
| Short-term investments | 17.4 | 0.0 | 58.9 | 95.2 | — | — | — |
| Receivables | 139 | 4.7 | 1.8 | 17.1 | — | — | — |
| Inventory | 26.8 | 0.0 | — | — | — | — | — |
| Net property, plant and equipment | 13.5 | 12.8 | 19.8 | 25.2 | — | — | — |
| Other intangible assets | — | — | — | 28.7 | 44.9 | — | — |
| Long-term investments | 80.0 | 144 | 0.0 | — | — | — | — |
| Current liabilities | 288 | 154 | 144 | 121 | 135 | 95.6 | 60.4 |
| Accounts payable | 36.2 | 9.6 | 10.7 | 11.6 | — | — | — |
| Long-term debt | 2,007 | 437 | 446 | 431 | 431 | 93.9 | 95.4 |
| Total debt | 1,862 | 1,731 | 1,740 | 1,724 | — | — | — |
| Total liabilities | 3,013 | 2,377 | 1,889 | 1,868 | 1,878 | 596 | 156 |
| Total equity (incl. minority) | -2,077 | -1,458 | -1,343 | -1,245 | — | — | — |
| Retained earnings | -3,821 | -3,096 | -2,561 | -1,918 | — | — | — |
| Minority interest | 10.0 | 10.3 | 11.7 | 9.7 | — | — | — |